Daewon Pharmaceutical Co., Ltd. (KRX:003220)

Market Cap	225.91B -23.7%
Revenue (ttm)	605.66B +1.3%
Net Income	-4.38B
EPS	-227.35
Shares Out	21.43M
PE Ratio	n/a
Forward PE	11.98
Dividend	250.00 (2.02%)
Ex-Dividend Date	Dec 29, 2025

Volume	546,315
Open	11,080.00
Previous Close	10,540.00
Day's Range	9,420.00 - 11,120.00
52-Week Range	8,070.00 - 14,700.00
Beta	0.16
Analysts	Strong Buy
Price Target	14,666.67 (+49.97%)
Earnings Date	Aug 13, 2026

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1958
• Employees: 1,283
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003220

Analyst Summary

According to 3 analysts, the average rating for 003220 stock is "Strong Buy." The 12-month stock price target is ₩14,667, which is an increase of 49.97% from the latest price.

Price Target

₩14,667

(49.97% upside)

Analyst Consensus: Strong Buy